Clinical guidance and International Classification of Disease coding analysis in the 2017 WHO classification of pituitary neuroendocrine tumors

doi:10.3969/j.issn.1672-6731.2022.01.008

Abstract

Abstract: The fourth edition of the latest classification of endocrine tumors has published by World Health Organization (WHO) in 2017, in which the theoretical basis of classification has been updated. With the discovery of specific transcription factors, the classification of pituitary adenomas which could not be diagnosed definitively and confused easily, whose prognosis is impossible to determine, has been defined. In this paper, the classification, diagnosis and prognosis of each pituitary adenoma were discussed according to the latest classification, and the corresponding disease codes were summarized based on International Classification of Disease-10 (ICD-10) and ICD-O.

Key words: Pituitary neoplasms, World Health Organization, International classification of diseases, Review

摘要： 2017年世界卫生组织发布第四版内分泌肿瘤分类（以下简称2017版分类），对垂体肿瘤分类的理论基础进行更新。垂体转录因子的发现使垂体腺瘤的分类更细化，使既往无法明确诊断、易混淆、无法判断预后的垂体腺瘤的分类得以明确。本文按照2017版分类对每种垂体腺瘤分类、诊断和预后进行分析，并结合国际疾病分类法-10（ICD-10）和ICD-O列出相应的疾病编码和形态学编码。

关键词: 垂体肿瘤, 世界卫生组织, 国际疾病分类法, 综述

GUAN Hong, GUO Shu-qin, JIA Tong-le. Clinical guidance and International Classification of Disease coding analysis in the 2017 WHO classification of pituitary neuroendocrine tumors[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2022, 22(1): 54-59.

关宏, 郭淑芹, 贾同乐. 2017版WHO垂体神经内分泌肿瘤分类临床指导及国际疾病分类法编码分析[J]. 中国现代神经疾病杂志, 2022, 22(1): 54-59.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2022.01.008

https://journal11.magtechjournal.com/cjcnn/EN/Y2022/V22/I1/54

References

[1] Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs[M]. 4th ed. Lyon: IARC Press, 2017: 11-45.
[2] Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary [J]. Acta Neuropathol, 2017, 134: 521-535.
[3] Molitch ME. Diagnosis and treatment of pituitary adenomas: a review[J]. JAMA, 2017, 317: 516-524.
[4] Hu XZ, Feng M, Wang RZ. A review of pituitary adenoma databases[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2021, 21: 132-140. 胡心至, 冯铭, 王任直. 垂体腺瘤数据库研究现状[J]. 中国现代神经疾病杂志, 2021, 21: 132-140.
[5] Raverot G, Jouanneau E, Trouillas J. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies[J]. Eur J Endocrinol, 2014, 170: R121-132.
[6] Molitch ME. Nonfunctioning pituitary tumors[J]. Handb Clin Neurol, 2014, 124: 167-184.
[7] Buchfelder M, Schlaffer S. Imaging of pituitary pathology[J]. Handb Clin Neurol, 2014, 124: 151-166.
[8] Rogers A, Karavitaki N, Wass JA. Diagnosis and management of prolactinomas and non - functioning pituitary adenomas[J]. BMJ, 2014, 349: g5390.
[9] Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV, Carroll PV, Korbonits M, Benediktsson R. The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population - based study [J]. Eur J Endocrinol, 2015, 173: 655-664.
[10] Tjörnstrand A, Gunnarsson K, Evert M, Holmberg E, Ragnarsson O, Rosén T, Filipsson Nyström H. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011 [J]. Eur J Endocrinol, 2014, 171: 519-526.
[11] Cooper O, Melmed S. Subclinical hyperfunctioning pituitary adenomas: the silent tumors[J]. Best Pract Res Clin Endocrinol Metab, 2012, 26: 447-460.
[12] Würth R, Thellung S, Corsaro A, Barbieri F, Florio T. Experimental evidence and clinical implications of pituitary adenoma stem cells[J]. Front Endocrinol (Lausanne), 2020, 11: 54.
[13] Chang M, Yang C, Bao X, Wang R. Genetic and epigenetic causes of pituitary adenomas[J]. Front Endocrinol (Lausanne), 2021, 11: 596554.
[14] Liu W, Zahr RS, McCartney S, Cetas JS, Dogan A, Fleseriu M. Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study [J]. Pituitary, 2018, 21: 454-462.
[15] Thodou E, Kontogeorgos G. Somatostatin receptor profile in pituitary thyrotroph adenomas[J]. Clin Neurol Neurosurg, 2020, 195: 105865.
[16] Bujko M, Kober P, Boresowicz J, Rusetska N, Paziewska A, Dąbrowska M, Piaścik A, Pękul M, Zieliński G, Kunicki J, Bonicki W, Ostrowski J, Siedlecki JA, Maksymowicz M. USP8 mutations in corticotroph adenomas determine a distinct gene expression profile irrespective of functional tumour status[J]. Eur J Endocrinol, 2019, 181: 615-627.
[17] Almeida JP, Stephens CC, Eschbacher JM, Felicella MM, Yuen KCJ, White WL, Mooney MA, Bernat AL, Mete O, Zadeh G, Gentili F, Little AS. Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers [J]. Pituitary, 2019, 22: 514-519.
[18] Singh V, Gupta K, Salunke P, Dhandapani SS. Null cell adenoma of the pituitary: pseudo - rosettes say it best when immunohistochemistry says nothing at all[J]. Head Neck Pathol, 2019, 13: 677-680.
[19] Ghadir M, Khamseh ME, Panahi - Shamsabad M, Ghorbani M, Akbari H, Mehrjardi AZ, Honardoost M, Jafar - Mohammadi B. Cell proliferation, apoptosis, and angiogenesis in non -functional pituitary adenoma: association with tumor invasiveness[J]. Endocrine, 2020, 69: 596-603.
[20] Aydin S, Comunoglu N, Ahmedov ML, Korkmaz OP, Oz B, Kadioglu P, Gazioglu N, Tanriover N. Clinicopathologic characteristics and surgical treatment of plurihormonal pituitary adenomas [J]. World Neurosurg, 2019, 130: e765-774.
[21] Goodsell KE, Ermer JP, Zaheer S, Kelz RR, Fraker DL, Wachtel H. Double adenoma as a cause of primary hyperparathyroidism: asymmetric hyperplasia or a distinct pathologic entity[J]? Am J Surg, 2021, 222: 483-489.
[22] Rasul FT, Jaunmuktane Z, Khan AA, Phadke R, Powell M. Plurihormonal pituitary adenoma with concomitant adrenocorticotropic hormone (ACTH) and growth hormone (GH) secretion: a report of two cases and review of the literature[J]. Acta Neurochir (Wien), 2014, 156: 141-146.
[23] Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, Ezzat S, Asa SL. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit - 1 lineage adenomas [J]. Mod Pathol, 2016, 29: 131-142.
[24] Zieliński G, Maksymowicz M, Podgórski J, Olszewski WT. Double, synchronous pituitary adenomas causing acromegaly and Cushing's disease: a case report and review of literature[J]. Endocr Pathol, 2013, 24: 92-99.
[25] Xu L, Khaddour K, Chen J, Rich KM, Perrin RJ, Campian JL. Pituitary carcinoma: two case reports and review of literature [J]. World J Clin Oncol, 2020, 11: 91-102.
[26] Nishioka H, Inoshita N. New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors[J]. Brain Tumor Pathol, 2018, 35: 57-61.
[27] Liu APY, Kelsey MM, Sabbaghian N, Park SH, Deal CL, Esbenshade AJ, Ploner O, Peet A, Traunecker H, Ahmed YHE, Zacharin M, Tiulpakov A, Lapshina AM, Walter AW, Dutta P, Rai A, Korbonits M, de Kock L, Nichols KE, Foulkes WD, Priest JR. Clinical outcomes and complications of pituitary blastoma [J]. J Clin Endocrinol Metab, 2021, 106: 351-363.
[28] Nadaf J, de Kock L, Chong AS, Korbonits M, Thorner P, Benlimame N, Fu L, Peet A, Warner J, Ploner O, Shuangshoti S, Albrecht S, Hamel N, Priest JR, Rivera B, Ragoussis J, Foulkes WD. Molecular characterization of DICER1 - mutated pituitary blastoma[J]. Acta Neuropathol, 2021, 141: 929-944.
[29] Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C. How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020 [J]. Cancers (Basel), 2020, 12: 514.
[30] Lee JC, Pekmezci M, Lavezo JL, Vogel H, Katznelson L, Fraenkel M, Harsh G, Dulai M, Perry A, Tihan T. Utility of Pit- 1 immunostaining in distinguishing pituitary adenomas of primitive differentiation from null cell adenomas[J]. Endocr Pathol, 2017, 28: 287-292.
[31] Hickman RA, Bruce JN, Otten M, Khandji AG, Flowers XE, Siegelin M, Lopes B, Faust PL, Freda PU. Gonadotroph tumours with a low SF-1 labelling index are more likely to recur and are associated with enrichment of the PI3K - AKT pathway[J]. Neuropathol Appl Neurobiol, 2021, 47: 415-427.
[32] Sjöstedt E, Bollerslev J, Mulder J, Lindskog C, Pontén F, Casar-Borota O. A specific antibody to detect transcription factor T - Pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours [J]. Acta Neuropathol, 2017, 134: 675-677.
[33] Turchini J, Sioson L, Clarkson A, Sheen A, Gill AJ. Utility of GATA - 3 expression in the analysis of pituitary neuroendocrine tumour (PitNET) transcription factors[J]. Endocr Pathol, 2020, 31: 150-155.
[34] Swanson AA, Erickson D, Donegan DM, Jenkins SM, Van Gompel JJ, Atkinson JLD, Erickson BJ, Giannini C. Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly[J]. Pituitary, 2021, 24: 192-206.
[35] Drummond J, Roncaroli F, Grossman AB, Korbonits M. Clinical and pathological aspects of silent pituitary adenomas[J]. J Clin Endocrinol Metab, 2019, 104: 2473-2489.
[36] Wang AS, Xu H, Zeng MH, Wang F. Identification of significant genes with invasive promotion in non-functional pituitary adenoma via bioinformatical analysis[EB]. [2021-01-19]. https://www.researchsquare.com/article/rs-146994/v1.
[37] Khalimova ZY, Urmanova YM. MON - 299 risk factors of re - growth of non - functional pituitary adenomas[J]. J Endocr Soc, 2020, 4(Suppl 1): 299.
[38] Jiang S, Zhu J, Feng M, Yao Y, Deng K, Xing B, Lian W, Wang R, Bao X. Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system[J]. Pituitary, 2021, 24: 564-573.
[39] Penn DL, Burke WT, Laws ER. Management of non-functioning pituitary adenomas: surgery [J]. Pituitary, 2018, 21: 145-153.
[40] Lloyd RV, Kovacs K, Young WF Jr. Pituitary tumors: introduction//DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization classifcation of tumours: pathology & genetics of tumours of endocrine organs[M]. 3rd ed. Lyon: IARC Press, 2004: 10-13.
[41] Zaidi HA, Cote DJ, Dunn IF, Laws ER Jr. Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas[J]. J Clin Neurosci, 2016, 34: 246-251.
[42] Yan XL, Zhang XB. Advances in research of invasion and recurrence of pituitary adenoma[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2017, 17: 541-545. 阎晓玲, 张学斌. 垂体腺瘤侵袭及复发相关因素研究进展[J]. 中国现代神经疾病杂志, 2017, 17: 541-545.
[43] Roncaroli F, Chatterjee D, Giannini C, Pereira M, La Rosa S, Brouland JP, Gnanalingham K, Galli C, Fernandes B, Lania A, Radotra B. Primary papillary epithelial tumour of the sella: expanding the spectrum of TTF - 1 - positive sellar lesions[J]. Neuropathol Appl Neurobiol, 2020, 46: 493-505.
[44] Mahavadi AK, Patel PM, Kuchakulla M, Shah AH, Eichberg D, Luther EM, Komotar RJ, Ivan ME. Central neurocytoma treatment modalities: a systematic review assessing the outcomes of combined maximal safe resection and radiotherapy with gross total resection[J]. World Neurosurg, 2020, 137: e176-182.
[45] Gupta S, Iorgulescu JB, Hoffman S, Catalino M, Bernstock JD, Chua M, Segar DJ, Fandino LB, Laws ER, Smith TR. The diagnosis and management of primary and iatrogenic soft tissue sarcomas of the sella[J]. Pituitary, 2020, 23: 558-572.
[46] McDonald WC, Banerji N, McDonald KN, Ho B, Macias V, Kajdacsy - Balla A. Steroidogenic factor 1, Pit - 1, and adrenocorticotropic hormone: a rational starting place for the immunohistochemical characterization of pituitary adenoma[J]. Arch Pathol Lab Med, 2017, 141: 104-112.

Please choose a citation manager

Content to export